COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 2340: Articles 23391-23400  | Next

Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile
Vatsalya, V., Li, F., Frimodig, J. C., Gala, K. S., Srivastava, S., Kong, M., Ramchandani, V. A., Feng, W., Zhang, X., McClain, C. J.
10.1101/2020.08.23.20177501 — Posted: 2020-08-25 Discussion: Onsite
Role of interfering substances in the survival of coronaviruses on surfaces and their impact on the efficiency of hand and surface disinfection
Szpiro, L., Pizzorno, A., Durimel, L., Julien, T., Traversier, A., Bouchami, D., Marie, Y., Rosa-Calatrava, M., Terrier, O., Moules, V.
10.1101/2020.08.22.20180042 — Posted: 2020-08-25
Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Abdelrahman, Z., Liu, Q., Jiang, S., Li, M., Zhang, Y., Wang, X.
10.1101/2020.08.24.20180638 — Posted: 2020-08-25 Discussion: Onsite
FLOW CYTOMETRY MULTIPLEXED METHOD FOR THE DETECTION OF NEUTRALIZING HUMAN ANTIBODIES TO THE NATIVE SARS-CoV-2 SPIKE PROTEIN
Horndler, L., Delgado, P., Balabanov, I., Cornish, G., Llamas, M. A., Serrano-Villar, S., Fresno, M., van Santen, H. M., Alarcon, B.
10.1101/2020.08.24.20180661 — Posted: 2020-08-25
A deterministic linear infection model to inform Risk-Cost-Benefit Analysis of activities during the SARS-CoV-2 pandemic
McCarthy, J. E., Dumas, B. A., McCarthy, M. T., Dewitt, B. D.
10.1101/2020.08.23.20180349 — Posted: 2020-08-25
An examination of COVID-19 mitigation efficiency among 23 countries
Chen, Y.-T., Yu, S.-H., Su, E. C.-Y.
10.1101/2020.08.23.20180554 — Posted: 2020-08-25
Bayesian Estimation of the Seroprevalence of Antibodies to SARS-CoV-2
Dong, Q., Gao, X.
10.1101/2020.08.23.20180497 — Posted: 2020-08-25 Discussion: Onsite
The health sector cost of different policy responses to COVID-19 in low- and middle- income countries
Torres Rueda, S., Sweeney, S., Bozzani, F., Vassall, A.
10.1101/2020.08.23.20180299 — Posted: 2020-08-25
Teamwork in the manufacturing workplace may hinder social distance
Kokubun, K.
10.1101/2020.08.22.20179994 — Posted: 2020-08-25
3D Printed N95 Equivalent for PPE Shortages: The Kansas City Mask
Dalla, S., Bacon, B., Ayres, J. M., Holmstead, S., Ahlberg Elliot, A. J.
10.1101/2020.08.23.20180513 — Posted: 2020-08-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).